GlassScriptPhysician profile
Tom S Connally
NPI 1326092370
$37,894.80
in general payments reported to CMS, 2019-2025
29 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $40.81 · 2021: $2,507 · 2022: $6,959 · 2023: $12K · 2024: $3,160 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $8,700 · Food and Beverage: $2,149 · Travel and Lodging: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,404.20 |
| Consulting Fee | $8,700.00 |
| Food and Beverage | $2,149.21 |
| Travel and Lodging | $1,911.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28,148.40 | 2021-2025 | Pteye Parathyroid Detection System, Nim-Response, Propel |
| Ascendis Pharma Endocrinology INC | $6,531.44 | 2023 | |
| Blueprint Medicines Corporation | $1,947.00 | 2021-2022 | |
| Hologic Sales and Service, LLC | $429.12 | 2023-2025 | Coolseal Generator |
| Tela Bio, INC. | $148.33 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Shire North American Group INC | $109.80 | 2019 | |
| Xeris Pharmaceuticals, INC. | $88.88 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $52.83 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Baxter Healthcare | $50.79 | 2025 | Perclot |
| Dexcom, INC. | $43.94 | 2023 | Dexcom G6 Transmitter |
| Innovation Technologies INC | $34.44 | 2023 | Irrisept |
| Davol INC. | $25.94 | 2021 | |
| Tei Biosciences INC | $25.46 | 2019 | |
| Horizon Therapeutics Plc | $25.24 | 2022 | |
| Corcept Therapeutics | $22.93 | 2024 | Korlym |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $18.94 | 2024 | Fibroscan |
| Cequr Corporation | $18.73 | 2025 | Cequr Simplicity |
| Chiesi USA, INC. | $16.72 | 2024 | Mycapssa |
| Amgen INC. | $16.67 | 2025 | Tepezza |
| Paratek Pharmaceuticals, INC. | $16.49 | 2025 | Nuzyra |
| Innocoll Pharmaceuticals Limited | $15.50 | 2022 | |
| Braintree Laboratories, INC. | $15.39 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.05 | 2023 | |
| Lilly USA, LLC | $14.46 | 2025 | Zepbound, Mounjaro |
| Olympus America INC. | $13.46 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $13.16 | 2020 | |
| Covidien LP | $12.26 | 2020 | |
| Baudax Bio INC. | $12.16 | 2022 | |
| Acell, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Connally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.